slides · global inventory
Table
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 60,568
Current window 42,691-42,720
Pages 2,019
Rows per page 30
Component
42,691-42,720 of 60,568
29
Includes detailed line items for compensation, non-compensation, operating income, other income, taxes, net income, and EPS.Houlihan Lokey | Investor Presentation Deck | 33 slides · Houlihan Lokey
Pitch deck Investor relations Beat · Financials1 hit
06
The slide uses a bar chart combined with a data table to highlight safety advantages. It includes a disclaimer about cross-trial comparisons.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Situation & ContextLoop · Golden Circle1 hit
14
The slide uses a table structure to contrast treatment efficacy and patient outcomes, with a bar chart at the bottom illustrating patient population growth.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Hypothesis Test1 hit
16
Includes a footer citing FDA approval precedents for similar single-arm studies.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Hypothesis Test1 hit
20
The slide uses a standard pharmaceutical pipeline table format.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · VisualizationLoop · Why Now1 hit
21
Includes a comparative table of clinical outcomes (ORR/CR/sCR) for NXC-201 vs competitors.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · VisualizationLoop · Why Now1 hit
24
The slide uses a red dashed box to highlight the primary efficacy metrics for comparison.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
26
The slide uses a red dashed box to highlight the key clinical data rows (ORR, CR, ICANS, CRS).Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
27
The slide uses a side-by-side comparison of two disease indications, showing clinical results, relevant competitor benchmarks, and market size.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
29
The table displays clinical trial data for NXC-201, specifically focusing on safety profiles and management interventions.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
30
The slide highlights specific safety metrics (CRS and ICANS) for two dosage groups (100x10^6 and 300x10^6 cells).Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
39
The slide uses a bubble chart to map clinical trials and a table to summarize drug performance metrics, highlighting low efficacy and high toxicity.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Satisfaction1 hit
40
The slide uses a combination of a conceptual chart and a data table to highlight efficacy and safety in a small sample size (n=4).Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Satisfaction1 hit
54
Highlights NXC-201's lower fludarabine dose and Carvykti's longer infusion window.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Satisfaction1 hit
55
The slide uses a combination of expert testimonials and a comparative clinical trial table to validate the outpatient administration model.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Satisfaction1 hit
13
The slide presents a sensitivity analysis of NII under various interest rate scenarios (+/- 100/200 bps).Independent Bank Corp | Results Presentation Deck | 27 slides · Independent Bank Corp
Conference presentation Investor relations Beat · Satisfaction1 hit
16
The slide uses a matrix structure to compare forward-looking guidance against recent quarterly performance.Independent Bank Corp | Results Presentation Deck | 27 slides · Independent Bank Corp
Conference presentation Investor relations Beat · Satisfaction1 hit
17
The slide uses a matrix structure to compare forward-looking guidance against realized quarterly performance.Independent Bank Corp | Results Presentation Deck | 27 slides · Independent Bank Corp
Conference presentation Investor relations Beat · Action1 hit
21
Includes a table of liquidity sources and a grouped bar chart showing liquidity coverage ratios over time.Independent Bank Corp | Results Presentation Deck | 27 slides · Independent Bank Corp
Conference presentation Investor relations 1 hit
24
Includes FDIC logo and 'Be Independent' branding.Independent Bank Corp | Results Presentation Deck | 27 slides · Independent Bank Corp
Conference presentation Investor relations 1 hit
25
The slide title 'Non-GAAP to GAAP Reconciliation' appears slightly mislabeled as the table presents standard GAAP financial metrics (Net Interest Income, Net Income, etc.) rather than a reconciliation of non-GAAP measures.Independent Bank Corp | Results Presentation Deck | 27 slides · Independent Bank Corp
Conference presentation Investor relations 1 hit
26
Standard financial disclosure slide for non-GAAP metrics.Independent Bank Corp | Results Presentation Deck | 27 slides · Independent Bank Corp
Conference presentation Investor relations 1 hit
27
The table reconciles Common shareholders' equity to Tangible common equity and Total assets to Tangible assets to derive the Tangible common equity ratio.Independent Bank Corp | Results Presentation Deck | 27 slides · Independent Bank Corp
Conference presentation Investor relations 1 hit
03
Jefferies Financial Group | Investor Presentation Deck | 74 slidesJefferies Financial Group | Investor Presentation Deck | 74 slides · Jefferies
Conference presentation Investor relations Beat · Setup1 hit
29
The chart displays annual growth in total capital returned, with a breakdown of components in the legend.Jefferies Financial Group | Investor Presentation Deck | 74 slides · Jefferies
Conference presentation Investor relations 1 hit
37
The slide uses a custom comparison table structure to show rank improvement alongside headcount metrics.Jefferies Financial Group | Investor Presentation Deck | 74 slides · Jefferies
Conference presentation Investor relations 1 hit
38
The slide highlights a divergence between company revenue growth and broader market fee pool contraction.Jefferies Financial Group | Investor Presentation Deck | 74 slides · Jefferies
Conference presentation Investor relations 1 hit
41
The table shows LTM Q3'23 global rankings for sponsor-backed M&A, ECM, and LevFin.Jefferies Financial Group | Investor Presentation Deck | 74 slides · Jefferies
Conference presentation Investor relations 1 hit
53
The slide uses a three-part additive structure to demonstrate progress across key business areas.Jefferies Financial Group | Investor Presentation Deck | 74 slides · Jefferies
Conference presentation Investor relations 1 hit
59
Includes a table comparing LAM, LAM ex Oak Hill, and HFRI Index returns.Jefferies Financial Group | Investor Presentation Deck | 74 slides · Jefferies
Conference presentation Investor relations 1 hit